TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03542279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Description: PE is performed every other day using a multi-filtrate apheresis device (Fresenius, Bad Homburg, Germany), and 5 times in total for each course. The plasma removed during PE is replaced with an equal volume of substitution (half 5% albumin with normal saline and half plasma). The plasma volume to be replaced was estimated according to the following formula: plasma volume (L) = 7.5%×weight (kg)×(1-hematocrit)×1000ml. Heparin was added to the exchange circuit to prevent blood clotting. The exchange rate was monitored, recorded, and balanced to prevent cardiovascular instability. Blood pressure and other vital signs were closely monitored every 15 minutes throughout the exchange.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma exchange (PE)
Description: PE is performed every other day using a multi-filtrate apheresis device (Fresenius, Bad Homburg, Germany), and 5 times in total for each course. The plasma removed during PE is replaced with an equal volume of substitution (half 5% albumin with normal saline and half plasma). The plasma volume to be replaced was estimated according to the following formula: plasma volume (L) = 7.5%×weight (kg)×(1-hematocrit)×1000ml. Heparin was added to the exchange circuit to prevent blood clotting. The exchange rate was monitored, recorded, and balanced to prevent cardiovascular instability. Blood pressure and other vital signs were closely monitored every 15 minutes throughout the exchange.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)
Description: IVIG is given 0.4 g/kg/d for each course for 5 days. IVMP is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)
Description: IVIG is given 0.4 g/kg/d for each course for 5 days. IVMP is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.
Study: NCT03423030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo supplied as powder for oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo supplied as powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 NCP
Description: PBTZ169 NCP supplied as powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 NCP
Description: PBTZ169 NCP supplied as powder for oral solution
Study: NCT01688245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Assessments & Feedback
Description: Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS Assessments
Description: Weekly post-weekend drinking outcome assessments
Study: NCT03184493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex plus Metformin
Description: This group patients will receive metformin and celebrex.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: This group patients will receive celebrex.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: This group patients will receive metformin.
Study: NCT00566982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Description: 60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
Study: NCT00779428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanespimycin
Description: Solution, IV~This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)
Study: NCT03691337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.25 % Injectable Solution
Description: Fascia iliaca block with volume 0.11 mL x subject height

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.25 % Injectable Solution
Description: Fascia iliaca block with volume 0.22 mL x subject height

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Fascia iliaca block with volume 0.11 mL x subject height
Study: NCT02582814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Description: Dapagliflozin, a blood glucose lowering drug. Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin, a blood glucose lowering drug. Oral dose
Study: NCT00528502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine is misted into the air that you breathe during the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline is misted into the air that you breathe during the surgery.
Study: NCT03530995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Development candidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Development candidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Development candidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Development candidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Development candidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Development candidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Perpetrator drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Perpetrator drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Perpetrator drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Perpetrator drug
Study: NCT02612324

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Business as Usual
Description: Teen pregnancy and STI prevention education left to the discretion of the school.
Study: NCT03180723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin
Description: Oral tablets
Study: NCT03780855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nerve scaffold
Description: It is a new kind of nerve scaffold with the microstructure of longitudinally oriented microchannels. It's made of collagen as the main raw material.
Study: NCT01088945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Discharge process
Description: Health Coaching prior to discharge, with an enhanced discharge binder to reinforce the teaching of the Health Coach

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Discharge process
Description: Health Coaching prior to discharge, with an enhanced discharge binder to reinforce the teaching of the Health Coach
Study: NCT02599129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
Study: NCT01228760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASG-5ME
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASG-5ME
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASG-5ME
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASG-5ME
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASG-5ME
Description: IV
Study: NCT00218634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-AD
Description: Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ETAU
Description: Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
Study: NCT02482597

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Periodic Acceleration
Description: A bed that translates back and forth at different frequencies while the subject lies supine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Periodic Acceleration
Description: A bed that translates back and forth at different frequencies while the subject lies supine
Study: NCT05390281

Intervention type: DIAGNOSTIC_TEST
Intervention: increase in serum creatinine
Description: any of the following: increase in serum creatinine by ≥ 0.3 mg/dl within 48 h of surgery or increase in serum creatinin
Study: NCT00678769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00678769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT03786081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab Vedotin
Description: Given into the vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab Vedotin
Description: Given into the vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab Vedotin
Description: Given into the vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab Vedotin
Description: Given into the vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab Vedotin
Description: Given into the vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab Vedotin
Description: Given into the vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab Vedotin
Description: Given into the vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab Vedotin
Description: Given into the vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given via IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given via IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given via IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given via IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given via IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given via IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given via IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given via IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given via IV
Study: NCT03489655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance Phase Intervention
Description: The CHW will utilize motivational interviewing techniques over phone calls to reinforce all asthma education provided in the AI phase, including asthma basics, triggers and reduction strategies, purpose of medications, and steps for proper medication use. The CHW will identify barriers the participant is facing in management of their asthma and set goals to overcome them. The CHW will encourage regular visits with the Primary Care Physician and assist with referrals for other medical and social services, as needed. CHWs will check-in with participants via phone, monthly for the first 6 months and bi-monthly in the remaining 6 months Participants will receive bi-monthly data collection follow-up phone calls by a Research Assistant.
Study: NCT02661555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study: NCT01932229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib treatment
Study: NCT03037476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based PFI
Description: A web-based 5 component Personalized Feedback Tool covering content on: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment Only
Description: The Assessment Only condition receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6 month follow-up, and 12 month follow-up.
Study: NCT05611567

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POSE2.0 procedure
Description: The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life style and behavioral intervention
Description: The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style and behavioral intervention
Description: The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.
Study: NCT01033006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Arm 1: catheter injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Arm 2: transarterial injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Arm 3: catheter and transarterial injection
Study: NCT03418311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Pessary-Group
Description: Placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at week of gestation 37+0. Except for placement/removal of cervical pessary the pregnant women will receive the usual care.
Study: NCT00263042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration
Study: NCT01152918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linkage-to-Care Component: Financial Incentive (FI)
Description: Test sites assigned to this arm will provide coupons to all people who are found to be HIV-infected after testing and who are not already linked to HIV care. The coupons can be redeemed at a participating HIV care site for gift cards.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linkage-to-Care Component: Standard of Care (SOC)
Description: Each person who receives an HIV positive test result, and is not currently in care, will be directed to HIV care sites using the site's SOC procedures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viral Suppression Component: FI
Description: HIV-infected participants who are receiving ART will be offered FIs upon the confirmation of each suppressed viral load measurement (less than 400 copies/mL).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Viral Suppression Component: SOC
Description: HIV-infected participants who are receiving ART will be offered support via the site's SOC procedures to attend HIV care site visits and remain adherent to their ART regimen in order to achieve and maintain viral load suppression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention for Positives Component: Counseling and SOC
Description: Participants will complete a computer-delivered counseling program that emphasizes HIV prevention strategies for HIV-infected people.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevention for Positives Component: SOC
Description: Participants will receive SOC from their HIV care site.
Study: NCT04622891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: clarithromycin 500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: azithromycin group
Study: NCT06795698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: enoxaparin 1mg/kg of ideal body weight subcutaneous every 24 hours in patients with eGFR \<30ml/min/1.73m2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin
Description: enoxaparin 1mg/kg of ideal body weight subcutaneous every 24 hours in patients with eGFR \<30ml/min/1.73m2
Study: NCT04622891

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control group
Study: NCT01986231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
Study: NCT02479087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-derived FVIII/VWF concentrate
Description: The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of \> 1: 4.5.~The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.~The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma).
Study: NCT01965769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No gastric residual evaluation
Description: Infants will not receive routine gastric residual evaluation prior to feeding.
Study: NCT04206254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp96
Description: heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.
Study: NCT03811769

Intervention type: OTHER
Group type: OTHER
Intervention: Best Medical Therapy
Description: The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mechanical Thrombectomy
Description: MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access).
Study: NCT03886740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reducing symptoms of Eustachian tube dysfunction
Description: One of two methods of reducing Eustachian Tube dysfunction will be performed and the Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores will be compared

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reducing symptoms of Eustachian tube dysfunction
Description: One of two methods of reducing Eustachian Tube dysfunction will be performed and the Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores will be compared
Study: NCT02489253

Intervention type: OTHER
Intervention: CT coronary angiogram and carotid ultrasound
Description: Scans in addition to routine clinical care

Intervention type: OTHER
Intervention: CT coronary angiogram and carotid ultrasound
Description: Scans in addition to routine clinical care
Study: NCT00519688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100 mg, BID
Study: NCT02720380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buteyko
Description: Intervention will be held twice a week during 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma education
Description: Educational interventions in relation to asthma will be given to children assigned to the control group.
Study: NCT00519688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur/Uracil
Description: 125 mg/m2, based on tegafur, BID